Skip to main content

FDA Approvals

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Jakafi a New Treatment Option for Chronic Graft-versus-Host Disease

Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer

Loretta Fala

Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation

Loretta Fala

Page 10 of 53
Results 91 - 100 of 522